Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 90 of 116

  1. CD19/CD20 Dual-CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Non-Hodgkin's Lymphoma

    phase 1 mab on hold

    1 trial

  2. CD19/CD20 Dual-CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Leukemia

    phase 1 mab completed

    1 trial

  3. CD7 UCAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    T-cell Leukemia

    phase 1 mab active

    1 trial

  4. CD70 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Metastatic Tumor

    phase 1 mab active

    4 trials

  5. CD70 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Renal Cell Carcinoma

    phase 1 mab active

    1 trial

  6. CD70 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Ovarian Cancer

    phase 1 mab active

    1 trial

  7. CD70-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Renal Cell Carcinoma (RCC)

    phase 1 mab active

    1 trial

  8. CDFF332A12101

    Novartis Pharmaceuticals

    Advanced, relapsed Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  9. CDKY709A12101C

    Novartis Pharmaceuticals

    Nasopharyngeal Carcinoma, Triple Negative Breast Cancer, Microsatellite Stable Colorectal Cancer, Non-Small Cell Lung Cancer, Cutaneous Melanoma

    phase 1 other active

    1 trial

  10. CEA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Colorectal Cancer

    phase 1 mab active

    1 trial

  11. CEA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Gastric Cancer

    phase 1 mab active

    1 trial

  12. CEA protein antigen plus BCG Vaccine Mix for percutaneous use

    Lxo Ireland Designated Activity Company

    Rectal Cancer

    phase 1 mab active

    1 trial

  13. CEA-targeted CAR-T (Intravenous)

    Chongqing Precision Biotech Co., Ltd

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 1 mab active

    1 trial

  14. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Peritoneal Metastases From Colorectal Cancer

    phase 1 mab active

    1 trial

  15. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Lung Cancer

    phase 1 mab active

    1 trial

  16. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Colorectal Cancer

    phase 1 mab active

    1 trial

  17. CEGF816X2102

    Novartis Pharmaceuticals

    Patients with EGFR-mutant Non Small Cell Lung Cancer

    phase 1 other active

    1 trial

  18. CEND-1

    LISATA THERAPEUTICS, INC.

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  19. CEP-11981 (kinase inhibitor)

    Teva Pharma GmbH

    Cancer

    phase 1 small molecule completed

    1 trial

  20. CEP-37440

    Teva Pharma GmbH

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  21. CEP-9722

    Teva Pharma GmbH

    Solid Tumor

    phase 1 small molecule completed

    1 trial

  22. CEP-9722

    Teva Pharma GmbH

    Solid Tumors or Mantle Cell Lymphoma

    phase 1 small molecule completed

    1 trial

  23. CEREAL-IPC 2016-010

    The George Institute

    Acute leukemia and myelodysplastic syndromes

    phase 1 other active

    1 trial

  24. CFKL480A02101

    Novartis Pharmaceuticals

    Advanced breast cancer and advanced NSCLC

    phase 1 other active

    1 trial

  25. CFT1946

    C4 Therapeutics

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  26. CFT8634

    C4 Therapeutics

    Synovial Sarcoma

    phase 1 small molecule terminated

    1 trial

  27. CFXX489A12101

    Novartis Pharmaceuticals

    Locally advanced or metastatic unresectable colorectal cancer (CRC), Locally advanced unresectable or metastatic breast cancer (BC), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC)

    phase 1 other active

    1 trial

  28. CG-806

    Aptose Biosciences

    Chronic Lymphocytic Leukemia

    phase 1 small molecule terminated

    1 trial

  29. CG-806

    Aptose Biosciences

    Acute Myeloid Leukemia

    phase 1 small molecule terminated

    1 trial

  30. CG0070

    CG Oncology

    Muscle-Invasive Bladder Carcinoma

    phase 1 small molecule completed

    1 trial

  31. CGCJ904A12101

    Novartis Pharmaceuticals

    Locally advanced unresectable or metastatic colorectal cancer (CRC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic soft tissue sarcoma (excluding GIST and Kaposi sarcoma), Locally advanced unresectable or metastatic HR+/HER2- ductal or lobular breast cancer (BC), Locally advanced unresectable or metastatic triple negative breast cancer (TNBC)

    phase 1 other active

    1 trial

  32. CGT4255

    Cogent Biosciences

    Advanced Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

  33. CHR-2797 (tosedostat)

    United Therapeutics Europe Ltd

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  34. CHS-006 (anti-TIGIT)

    Coherus Oncology

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  35. CHS-1000

    Coherus Oncology

    Advanced or Metastatic Solid Tumors

    phase 1 mab active

    1 trial

  36. CHS-114

    Coherus Oncology

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  37. CHS-114

    Coherus Oncology

    Metastatic Solid Tumor

    phase 1 small molecule active

    1 trial

  38. CHS-388

    Coherus Oncology

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

  39. CIAG933A12101

    Novartis Pharmaceuticals

    Advanced mesothelioma or other solid tumors harboring certain molecular alterations in the Hippo pathway

    phase 1 other active

    1 trial

  40. CITY

    Pari Pharma GmbH

    Cutaneous T-cell lymphomas (CTCL)

    phase 1 other active

    1 trial

  41. CKFA115A12101

    Novartis Pharmaceuticals

    Thymic Carcinoma, Nasopharyngeal Cancer, Anal Cancer, Head and Neck Squamous Cell Carcinoma, Epithelial Ovarian Cancer, Cutaneous melanoma, Mesothelioma, Non-small cell lung cancer, Esophagogastric Cancer, Triple negative breast cancer, Microsatellite Instability High Colorectal Cancer, Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  42. CLDK378A2120C

    Novartis Pharmaceuticals

    Non-small cell lung cancer

    phase 1 other active

    1 trial

  43. CLL1 and CD38 Dual-Target CAR-T Cell Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  44. CLN-049

    Cullinan Therapeutics

    Relapsed/Refractory Acute Myeloid Leukemia (AML)

    phase 1 small molecule active

    1 trial

  45. CLN-049-002

    Cullinan Therapeutics

    Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD)

    phase 1 other active

    1 trial

  46. CLN-617

    Cullinan Therapeutics

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  47. CLN-619

    Cullinan Therapeutics

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  48. CLN-619-001

    Cullinan Therapeutics

    Solid tumors, Non-Small Cell Lung Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, breast cancer, gastrointestinal cancer

    phase 1 other active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.